[
    {
        "contents": "data\\EPI\\20161221-221556.news",
        "description": "[CNW Group] - ESSA Pharma Provides Business Update and Announces Fourth Quarter and Year Ended September 30, 2016 Financial Results",
        "guid": "yahoo_finance/3210664562",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-provides-business-announces-133000227.html",
        "pubDate": "Wed, 14 Dec 2016 13:30:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Provides Business Update and Announces Fourth Quarter and Year Ended September 30, 2016 Financial Results"
    },
    {
        "contents": "data\\EPI\\20161221-221557.news",
        "description": "[PR Newswire] - HOUSTON and VANCOUVER, Dec. 14, 2016 /PRNewswire/ - ESSA Pharma Inc. (\"ESSA\" or the \"Company\") (NASDAQ: EPIX, TSX: EPI), a clinical stage pharmaceutical company focused on developing ...",
        "guid": "yahoo_finance/1885742710",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-provides-business-announces-133000425.html",
        "pubDate": "Wed, 14 Dec 2016 13:30:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Provides Business Update and Announces Fourth Quarter and Year Ended September 30, 2016 Financial Results"
    },
    {
        "contents": "data\\EPI\\20161221-221559.news",
        "description": "[CNW Group] - ESSA Secures US$10 Million Term Loan from Silicon Valley Bank",
        "guid": "yahoo_finance/2789709029",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-secures-us-10-million-133000448.html",
        "pubDate": "Mon, 21 Nov 2016 13:30:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Secures US$10 Million Term Loan from Silicon Valley Bank"
    },
    {
        "contents": "data\\EPI\\20161221-221601.news",
        "description": "[PR Newswire] - HOUSTON and VANCOUVER, Nov. 21, 2016 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) (\"ESSA\" or the \"Company\"), a pharmaceutical company focused on the development of small molecule drugs for the treatment of prostate cancer, announced that it has secured a US$10 million growth capital term loan facility from Silicon Valley Bank (\"SVB\" or the \"Bank\"). Under the loan and security agreement, the Company will initially draw down US$8 million and has a conditional option to receive an additional US$2 million (collectively, the \"Term Loans\"). The proceeds from the Term Loans will be used for the Company's future working capital needs.",
        "guid": "yahoo_finance/1117161473",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-secures-us-10-million-133000369.html",
        "pubDate": "Mon, 21 Nov 2016 13:30:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Secures US$10 Million Term Loan from Silicon Valley Bank"
    },
    {
        "contents": "data\\EPI\\20161221-221603.news",
        "description": "[CNW Group] - ESSA Pharma to present at Rodman & Renshaw 18th Annual Global Investment Conference",
        "guid": "yahoo_finance/4241491667",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-present-rodman-renshaw-123600504.html",
        "pubDate": "Mon, 12 Sep 2016 12:36:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma to present at Rodman & Renshaw 18th Annual Global Investment Conference"
    },
    {
        "contents": "data\\EPI\\20161221-221605.news",
        "description": "[PR Newswire] - HOUSTON, TX and VANCOUVER, Canada, Sept. 12, 2016 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) (\"ESSA\" or the \"Company\") a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced David R. Parkinson, President and Chief Executive Officer will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference in New York City on Tuesday September 13th at 11:15 AM Eastern Time at the Lotte New York Palace Hotel. Dr. Parkinson will provide a corporate overview of the Company's business and will be available for one-on-one meetings from September 12 \u2013 13, 2016. ESSA's Chief Financial Officer, David S. Wood and ESSA's Chief Operating Officer, Peter Virsik, will be also in attendance. A live audio webcast of the presentation may be accessed by visiting http://wsw.com/webcast/rrshq26/epi and will be available at the Company's website(www.essapharma.com) after the conference.",
        "guid": "yahoo_finance/1511443884",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-present-rodman-renshaw-123600996.html",
        "pubDate": "Mon, 12 Sep 2016 12:36:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma to present at Rodman & Renshaw 18th Annual Global Investment Conference"
    },
    {
        "contents": "data\\EPI\\20161221-221606.news",
        "description": "[PR Newswire] - HOUSTON, TX and VANCOUVER, Aug. 12, 2016 /PRNewswire/ - ESSA Pharma Inc. (\"ESSA\" or the \"Company\") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the third quarter and three months ended June 30, 2016. Amounts, unless specified otherwise, are expressed in United States dollars and in accordance with International Financial Reporting Standards (\"IFRS\"). ESSA recorded a net loss of $3.9 million ($0.13 per common share) for the three months ended June 30, 2016, compared to a net loss of $4.9 million ($0.29 per common share) for the three months ended June 30, 2015. Research and Development (\"R&D\") expenditures for the three month period were $3.4 million compared to $2.6 million for 2015. R&D expenditures in the period are primarily related to manufacturing and clinical costs as the Company continues its work in the clinical development stage with respect to clinical candidate EPI-506.",
        "guid": "yahoo_finance/3641838387",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-200000191.html",
        "pubDate": "Fri, 12 Aug 2016 20:00:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016"
    },
    {
        "contents": "data\\EPI\\20161221-221608.news",
        "description": "[CNW Group] - ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016",
        "guid": "yahoo_finance/2895264434",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-200000130.html",
        "pubDate": "Fri, 12 Aug 2016 20:00:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016"
    },
    {
        "contents": "data\\EPI\\20161221-221610.news",
        "description": "[CNW Group] - ESSA Names Peter Virsik as Executive Vice President & Chief Operating Officer",
        "guid": "yahoo_finance/50574886",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-names-peter-virsik-executive-121500154.html",
        "pubDate": "Mon, 01 Aug 2016 12:15:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Names Peter Virsik as Executive Vice President & Chief Operating Officer"
    },
    {
        "contents": "data\\EPI\\20161221-221611.news",
        "description": "[PR Newswire] - Mr. Virsik will be responsible for leading ESSA's overall business development and corporate strategy as the Company further advances its clinical development plan for the novel prostate cancer therapeutic EPI-506.",
        "guid": "yahoo_finance/570810290",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-names-peter-virsik-executive-121500020.html",
        "pubDate": "Mon, 01 Aug 2016 12:15:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Names Peter Virsik as Executive Vice President & Chief Operating Officer"
    },
    {
        "contents": "data\\EPI\\20161221-221613.news",
        "description": "[CNW Group] - ESSA Pharma Inc. Reports Financial Results for the Second Quarter Ended March 31, 2016",
        "guid": "yahoo_finance/470368004",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-201500563.html",
        "pubDate": "Fri, 13 May 2016 20:15:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Inc. Reports Financial Results for the Second Quarter Ended March 31, 2016"
    },
    {
        "contents": "data\\EPI\\20161221-221614.news",
        "description": "[PR Newswire] - HOUSTON and VANCOUVER, May 13, 2016 /PRNewswire/ - ESSA Pharma Inc. (\"ESSA\" or the \"Company\") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the second quarter and three months ended March 31, 2016. Amounts, unless specified otherwise, are expressed in United States dollars and in accordance with International Financial Reporting Standards (\"IFRS\"). Dr. David R. Parkinson was appointed as the company's President and Chief Executive Officer on January 7th, 2016, bringing significant drug development and business experience to the Company.",
        "guid": "yahoo_finance/1755382999",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-201500067.html",
        "pubDate": "Fri, 13 May 2016 20:15:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Inc. Reports Financial Results for the Second Quarter Ended March 31, 2016"
    },
    {
        "contents": "data\\EPI\\20161221-221616.news",
        "description": "[PR Newswire] - HOUSTON, TX and VANCOUVER, March 21, 2016 /PRNewswire/ - ESSA Pharma Inc. (\"ESSA\" or the \"Company\") (TSX: EPI, NASDAQ: EPIX) announced today that Eventide Funds purchased 370,566 Common Shares from each of Marianne Sadar and Raymond Andersen, both directors and officers of the Company, and 311,612 Common Shares from Robert Rieder, at a price of US$3.00 per Common Share. The Company did not receive any proceeds from the transaction.",
        "guid": "yahoo_finance/413139100",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-secondary-000200885.html",
        "pubDate": "Tue, 22 Mar 2016 00:02:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Announces Closing of a Secondary Offering"
    },
    {
        "contents": "data\\EPI\\20161221-221618.news",
        "description": "[CNW Group] - ESSA Pharma Announces Closing of a Secondary Offering",
        "guid": "yahoo_finance/2318486430",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-secondary-000200740.html",
        "pubDate": "Tue, 22 Mar 2016 00:02:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Announces Closing of a Secondary Offering"
    },
    {
        "contents": "data\\EPI\\20161221-221619.news",
        "description": "[PR Newswire] - HOUSTON, TX and VANCOUVER, March 21, 2016 /PRNewswire/ - ESSA Pharma Inc. (\"ESSA\" or the \"Company\") (TSX: EPI, NASDAQ: EPIX) is pleased to announce that it has closed a non-brokered private placement (the \"Private Placement\") of 1,666,666 common shares in the capital of the Company (\"Common Shares\") at US$3.00 per Common Share to Eventide Funds for gross proceeds of approximately US$5 million. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including funding research and development, preclinical and clinical expenses, and corporate costs.",
        "guid": "yahoo_finance/2725710669",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-us-235200974.html",
        "pubDate": "Mon, 21 Mar 2016 23:52:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Announces Closing of US$5 Million Private Placement"
    },
    {
        "contents": "data\\EPI\\20161221-221621.news",
        "description": "[CNW Group] - ESSA Pharma Announces Closing of US$5 Million Private Placement",
        "guid": "yahoo_finance/3443670883",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-us-235200433.html",
        "pubDate": "Mon, 21 Mar 2016 23:52:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Announces Closing of US$5 Million Private Placement"
    },
    {
        "contents": "data\\EPI\\20161221-221623.news",
        "description": null,
        "guid": "yahoo_finance/4069150026",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-results-021500593.html",
        "pubDate": "Fri, 11 Mar 2016 02:15:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders"
    },
    {
        "contents": "data\\EPI\\20161221-221624.news",
        "description": "[PR Newswire] - HOUSTON, TEXAS and VANCOUVER, BC, March 10, 2016 /PRNewswire/ - ESSA Pharma Inc. (\"ESSA\" or the \"Company\") (TSX: EPI, NASDAQ: EPIX) is pleased to announce the results of the votes on ...",
        "guid": "yahoo_finance/2641786499",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-results-021500824.html",
        "pubDate": "Fri, 11 Mar 2016 02:15:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders"
    },
    {
        "contents": "data\\EPI\\20161221-221627.news",
        "description": null,
        "guid": "yahoo_finance/2322036769",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-230000606.html",
        "pubDate": "Fri, 12 Feb 2016 23:00:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Inc. reports financial results for the first quarter ended December 31, 2015"
    },
    {
        "contents": "data\\EPI\\20161221-221628.news",
        "description": null,
        "guid": "yahoo_finance/2532768134",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-230000135.html",
        "pubDate": "Fri, 12 Feb 2016 23:00:00 GMT",
        "source": "data\\EPI\\20161221.rss",
        "title": "ESSA Pharma Inc. reports financial results for the first quarter ended December 31, 2015"
    },
    {
        "contents": "data\\EPI\\20170104-090416.news",
        "description": null,
        "guid": "yahoo_finance/2187120253",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-us-212400546.html",
        "pubDate": "Thu, 14 Jan 2016 21:24:00 GMT",
        "source": "data\\EPI\\20170104.rss",
        "title": "ESSA Pharma Announces Closing of US$15 Million Private Placement"
    },
    {
        "contents": "data\\EPI\\20170104-090418.news",
        "description": null,
        "guid": "yahoo_finance/2605219249",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-us-212400995.html",
        "pubDate": "Thu, 14 Jan 2016 21:24:00 GMT",
        "source": "data\\EPI\\20170104.rss",
        "title": "ESSA Pharma Announces Closing of US$15 Million Private Placement"
    },
    {
        "contents": "data\\EPI\\20170130-090444.news",
        "description": "[CNW Group] - ESSA receives US$4.0 million grant payment from Cancer Prevention Research Institute of Texas",
        "guid": "yahoo_finance/2631388545",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-receives-us-4-0-131500662.html",
        "pubDate": "Mon, 30 Jan 2017 13:15:00 GMT",
        "source": "data\\EPI\\20170130.rss",
        "title": "ESSA receives US$4.0 million grant payment from Cancer Prevention Research Institute of Texas"
    },
    {
        "contents": "data\\EPI\\20170130-090446.news",
        "description": "[PR Newswire] - NASDAQ: EPIX) (\"ESSA\" or the \"Company\") a pharmaceutical company, currently in the clinical development stage, focused on the development of small molecule drugs for the treatment of prostate cancer announced today the receipt of a US$4.0 million payment from the Cancer Prevention Research Institute of Texas (\"CPRIT\"). The payment is part of a total non-dilutive grant of US$12.0 million, repayable out of potential product revenues, which was originally awarded in February 29, 2014. The payment recognizes eligible expenditures made by ESSA in conducting the Phase 1 dose escalation trial currently underway, and also costs incurred in preparation for the Phase 2 dose expansion clinical study expected to begin later this year. The Company is eligible to receive a further US$1.4 million upon satisfactory completion of financial and compliance filings with CPRIT.",
        "guid": "yahoo_finance/3841442933",
        "link": "http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-receives-us-4-0-131500464.html",
        "pubDate": "Mon, 30 Jan 2017 13:15:00 GMT",
        "source": "data\\EPI\\20170130.rss",
        "title": "ESSA receives US$4.0 million grant payment from Cancer Prevention Research Institute of Texas"
    }
]